https://sweden.dlapiper.com/en/news/dla-piper-has-advised-perimed-connection-strategic-investment-serendipity-partners



DLA Piper has advised Perimed in connection with the strategic investment from Serendipity Partners



Mikael Moreira Partner



Erik Rosberg Senior Associate

DLA Piper has advised Perimed AB ("**Perimed**"), a Swedish MedTech company and world leader in instruments for advanced vascular diagnostics, in connection with the strategic investment from Serendipity Partners, a leading Nordic healthcare growth investor. The strategic investment will fuel Perimed's expansion plans, particularly in the United States.

Read the press release by Perimed here.

Services

Corporate, Emerging Growth and Venture Capital